Navigation Links
Study Sheds Light on Young Suburban Heroin Users
Date:10/18/2011

HINSDALE, Ill., Oct. 18, 2011 /PRNewswire-USNewswire/ -- Researchers found Chicago area suburban heroin users have little knowledge about the drug and its effects when they first use it, and they often substitute heroin after becoming addicted to prescription pain medications.

Those are some of the conclusions from a 10-month study, entitled "Understanding Suburban Heroin Use," for the Robert Crown Center for Health Education's Reed Hruby Heroin Prevention Project.  The research team from Roosevelt University's Illinois Consortium on Drug Policy conducted in-depth, confidential interviews with 15 current and former young heroin users, ages 22 to 31 years old, from Chicago's western suburbs. Respondents from western Cook, DuPage and Will counties discussed how they began using heroin and what they knew about heroin when they first tried the drug.

Results indicate young, suburban heroin users believed when they "snorted or sniffed" heroin they were less likely to become addicted.  Nearly two-thirds of the study respondents said they turned to heroin after first using prescription pain medications, or as a way to "come down" from cocaine use.  Co-authors Kathie Kane-Willis and Stephanie Schmitz screened more than 50 candidates and developed a sample of 15 heroin users for more extensive questioning.  They also conducted focus groups with 28 young suburban participants who had been involved with drugs in high school, and surveyed more than 100 suburban parents, in an effort to paint a picture of Chicago-area suburban heroin users.

According to the report, the heroin-involved interviewees reported they initiated to the drug in one of three ways.

  • They had first taken and often became dependent on pain pills (Oxycontin or Vicodin) before they transitioned to heroin.  
  • They were cocaine users and tried heroin to help them "come down" or sleep after a cocaine binge.
  • They tried heroin after experimenting with many other drugs.

Researchers found that for some, heroin use started early.  Twenty percent of the group reported their first heroin use at age 15, though the average age of first use was 18.  The majority of the interviewees reported little or no knowledge about heroin dependence or the withdrawal syndrome associated with it. More than 75% of respondents either self-reported or exhibited signs of a co-occurring mental health condition during the interview process including depression, anxiety, ADHD or bipolar disorder.

In addition, among the 105 suburban parents who were surveyed for the study, nearly 50 percent said they did not know where to go to get accurate drug information. Robert Crown Center CEO Kathleen Burke commented, "The message here is that educators, parents and other influencers must paint an accurate and authentic picture of the risks and harm associated with heroin in order to reach youth.  Families need more information to create open lines of communication, so that young people have a safe place to talk about their problems and pain without turning to heroin."

For more information contact:
Joan Drummond Olson
Director of Communications
(630) 325-1900 ext. 10, jdolson@robertcrown.org


'/>"/>
SOURCE Robert Crown Center for Health Education
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Boston Scientific Completes Enrollment in Benign Stricture Study of WallFlex® Biliary RX Stent
2. New Study Shows Neonatologists and Parents of NICU Infants Share Concern Regarding Newborn Exposure to Animal-Derived Medications
3. PLC Systems Receives FDA Approval to Commence Pivotal Study of RenalGuard in the U.S.
4. Medco, Quest Diagnostics Personalized Medicine Study Yields Additional Clues about Patient Engagement
5. Study Highlights Emerging Approaches to Medical Education in the Pharmaceutical Sector
6. Good Start Genetics to Announce Validation Study Results for its Next-Generation DNA Sequencing Platform During an Oral Presentation at the 2011 Annual Meeting of the American Society for Reproductive Medicine (ASRM)
7. Merrimack Pharmaceuticals Initiates Enrollment in a Neoadjuvant Phase 2 Study of MM-121 with Paclitaxel in HER2-negative Breast Cancer Patients
8. Study Shows That Roches Investigational Drug for Alzheimers Disease Removes Amyloid Plaques From the Brain
9. Hernia Publishes a Unique Three Year Pre-Clinical Study of absorbable TIGR® Matrix Surgical Mesh Versus a Permanent Mesh
10. Hologic Announces Six-year Follow-up Results from the MammoSite Targeted Breast Irradiation Registry Study
11. Bioness Inc. Announces Completion of Enrollment in Its FASTEST L300 Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/20/2017)... 2017 Research and Markets has announced ... Services Market Analysis By Service (Manufacturing, Research), By Country, (Brazil, ... 2025" report to their offering. ... The Latin American pharmaceutical contract manufacturing services ... Low drug registration cost in Latin American countries ...
(Date:4/19/2017)... April 19, 2017  IRIDEX Corporation (Nasdaq: ... results for the first quarter 2017 after the close ... management team will host a corresponding conference call beginning ... Investors interested in listening to the conference call ... callers or (703) 326-3030 for international callers, using conference ...
(Date:4/19/2017)... The Global Effective Microorganisms (EM) Market ... has covered and analysed the potential of Global Effective Microorganisms ... shares and growth factors. The report identifies and analyses the ... the global market. ... 152 Tables and Figures, 6 Major Company Profiles, spread across ...
Breaking Medicine Technology:
(Date:4/26/2017)... ... April 26, 2017 , ... ... thrilled to announce the ATA 2017 President’s Awards recipients, comprised of organizations ... superior healthcare delivery. , The ATA 2017 President’s Awards recognize individuals ...
(Date:4/26/2017)... ... April 26, 2017 , ... ... Excellence specializes in pelvic conditions and has helped many women become pregnant upon ... a combination of office-based and simple outpatient evaluations. We can provide the ...
(Date:4/26/2017)... ... April 26, 2017 , ... ... for sponsors and CROs to speed clinical development, has released the industry’s ... Bioclinica AGILE RTSM provides seamless clinical supply forecasting and management ...
(Date:4/25/2017)... (PRWEB) , ... April 25, ... ... based in Newport Beach, California, committed to raising awareness for Duchenne muscular ... results from its randomized CAP-1002 (cardiosphere-derived cells) Phase I/II HOPE clinical trial ...
(Date:4/25/2017)... ... April 25, 2017 , ... Lake Park Dental is now accepting ... Invisalign® in Lutz, FL. With the help of this highly-effective, yet convenient system, ... potential complications, more discretion and less pain. , Drs. Sarah Jockin, Nicole Morganti, ...
Breaking Medicine News(10 mins):